Menu
Search
|

Menu

Close
X

Assembly Biosciences Inc ASMB.OQ (NASDAQ Stock Exchange Capital Market)

42.76 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 42.76
Open --
Volume --
3m Avg Volume 79,421
Today’s High --
Today’s Low --
52 Week High 66.89
52 Week Low 20.83
Shares Outstanding (mil) 17.36
Market Capitalization (mil) 613.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
9
FY16
0
FY15
0
EPS (USD)
FY18
-0.803
FY17
-2.908
FY16
-2.569
FY15
-1.879
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
201.45
5.73
Price to Book (MRQ)
vs sector
10.84
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-45.44
14.61
Return on Equity (TTM)
vs sector
-64.48
16.34

EXECUTIVE LEADERSHIP

William Ringo
Independent Non-Executive Chairman of the Board, Since 2015
Salary: --
Bonus: --
Derek Small
President, Chief Executive Officer, Director, Since 2015
Salary: $160,416.00
Bonus: $116,667.00
Graham Cooper
Chief Financial Officer, Chief Operating Officer and Principal Financial Officer and Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Thomas Rollins
Chief Development Officer, Since 2017
Salary: --
Bonus: --
Alan Lewis
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11711 N Meridian St Ste 310
CARMEL   IN   46032-4549

Phone: +1212.5544388

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

SPONSORED STORIES